<DOC>
	<DOCNO>NCT02995330</DOCNO>
	<brief_summary>Men progressive metastatic Castration-Resistant Prostate Cancer post first-line treatment either androgen deprivation therapy alone androgen deprivation therapy plus docetaxel identify related female donor ( mother sister , daughter , second degree relative granddaughter niece ) undergo bone marrow transplantation follow post-transplant Cytoxan ( PT/Cy ) testosterone .</brief_summary>
	<brief_title>Sex-Mismatched Allogeneic Bone Marrow Transplantation Men With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>Men undergo pre-transplant screening evaluation enrol study . Subjects treated standard non-myeloablative conditioning regimen consist Fludarabine 30 mg/m2 IV Days -6 -2 ; Cy 14.5 mg/kg IV Days -6 -5 ; Total body irradiation ( TBI ) 200 cGy Day -1 . On Day 0 , patient infuse non-T-cell deplete bone marrow relate female donor . Patients receive GVHD prophylaxis consist : Cy 50mg/kg IV Days +3 +4 ; tacrolimus ( IV PO ) begin Day +5 [ dose adjust maintain trough level 5-15 ng/mL ] day+180 ; Mycophenolate mofetil ( MMF ) 15 mg/kg PO TID , maximum dose 1g TID begin Day +5 Day +35 . Patients receive filgrastim ( G-CSF ) 5 mcg/kg/day begin Day +5 continue ANC ≥ 1500/mm3 . Lastly , produce maintenance tumor antigen stimulation , patient maintain continuous LHRH agonist/antagonist therapy ( previously surgically castrate ) suppress endogenous testosterone production throughout treatment period ; testosterone cypionate 400 mg IM administer Day +60 , +90 , +120 ( every 30 day x 3 dos ) . Patients achieve biochemical CR stop LHRH agonist/antagonist treatment day 180 . Patients follow 3 year post-BMT .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>Performance status ≤1 Age ≥18 year ≤ 75 year old Histologicallyconfirmed adenocarcinoma prostate Treated continuous androgen ablative therapy ( either surgical castration LHRH agonist/antagonist ) document castrate level serum testosterone ( &lt; 50 ng/dl ) Metastatic disease radiographically document CT bone scan Patient must HLA type high resolution use DNA base type follow locus : HLAA , B , C , DRB1 Patient must available one potential first ( biologic mother , sister , halfsister , daughter ) seconddegree relate female donor . Mothers daughter 100 % chance haploidentical match , sister 75 % chance match haploidentical , second degree relatives 50 % chance haploidentical match . The donor recipient must HLA identical least one antigen HLAA , B , C HLADRB1 . Screening PSA must ≥ 1.0 ng/mL . Prior therapy one second line hormonal therapy allow ( i.e . bicalutamide , nilutamide , flutamide , ketoconazole , abiraterone , enzalutamide , ARN509 ) . Prior docetaxel ( ≤ 6 cycle ) first line therapy Cardiac ejection fraction rest must ≥ 40 % Acceptable liver function : Bilirubin &lt; 2.5 mg/dL ( unless due Gilbert 's disease , AST ( SGOT ) ALT ( SGPT ) &lt; 5 time upper limit normal . Acceptable renal function : Serum creatinine within normal range . Pulmonary function : DLCO ( correct hemoglobin ) , FEV1 FVC &gt; 50 % predict . At least 4 wks since prior radiation surgery full recovery ( persistent toxicity ≥ Grade 1 ) Ability understand willingness sign write informed consent document . Prior treatment SipuleucelT , radium223 , strontium89 , samarium153 Prior chemotherapy ( docetaxel , cabazitaxel ) castrate resistant prostate cancer Evidence serious and/or unstable preexist medical , psychiatric condition ( include laboratory abnormality ) could interfere patient safety provision inform consent participate study Active uncontrolled infection , include know history HIV/AIDS hepatitis B C. Any psychological , familial , sociological , geographical condition could potentially interfere compliance study protocol followup schedule .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Castration-Resistant Prostate Cancer</keyword>
	<keyword>Bone Marrow Transplantation</keyword>
</DOC>